Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective?
Significant health care resources are today spent on diagnosing and treatment of early breast cancer. 98 consecutive patients referred to our oncological unit between January 1997 and June 1998 underwent an evaluation programme including thoracic X-ray, liver and bone scan and blood test. When findings suspected for metastatic disease were revealed, further examinations (CT-scan, MRI) were performed. Whereas the screening programme disclosed four cases (4%) of distant metastasis, several patients had to suffer the psychological distress of false positive results. One in three suspicious thoracic X-rays, two in two liver scans and 18 out of 21 suspected bone scans were concluded false positive in terms of metastatic disease. A screening programme including blood test and thoracic X-ray alone, would have mis-classified one out of 98 patients. This study indicated thoracic X-ray and blood test as being sufficient and 110 Pounds per patient screened could be saved.